XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
Equity (Tables)
6 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Common Stock Reserved for Issuance
The Company has shares of common stock reserved for issuance as follows (in thousands):
September 30, 2022
Common stock warrants641 
2010 Plan
Options outstanding22,134 
2021 Plan
Awards outstanding
1,491 
Shares available for future grant31,480 
2021 ESPP6,321 
Options outstanding outside the plans2,655 
Total64,722 
Stock Option Activity
Stock option activities within the Plans as well as outside of the Plans were as follows:
Number of Shares
(in thousands)
Weighted-Average
Exercise Price
Average Remaining Contractual Term
(in years)
Aggregate Intrinsic Value (in thousands)
Balance, March 31, 202226,983 $4.15 7.63$1,293,545 
Options exercised(1,787)3.09 
Options forfeited or expired(407)5.78 
Balance, September 30, 202224,789 4.20 7.17644,960 
Vested and exercisable as of September 30, 202211,186 2.12 6.05314,388 
Vested and expected to vest as of September 30, 202223,204 4.11 7.11605,967 
Stock Options Valuation Assumptions
The fair value of each option on the date of grant is determined using the Black-Scholes option-pricing model with the assumptions set forth in the following table:
Six Months Ended September 30, 2021
Fair value of common stock
$18.41 - $21.41
Volatility
46.5% - 47.0%
Risk-free interest rate
0.77% - 1.02%
Expected term (in years)
5.00 - 6.09
Expected dividend
—%
Restricted Stock Unit Activity
The following table summarizes RSU activity during the six months ended September 30, 2022 (in thousands, except per share information):
Number of SharesWeighted-
Average
Grant Date Fair Value
Unvested balance, March 31, 2022534 $68.23 
Granted900 34.78 
Vested(91)62.76 
Forfeited(47)41.14 
Unvested balance, September 30, 20221,296 46.37 
Stock-Based Compensation Expense
Total stock-based compensation expense recognized in the condensed consolidated statements of operations was as follows (in thousands):
Three Months Ended September 30,Six Months Ended September 30,
2022202120222021
Cost of revenue$2,392 $793 $4,514 $1,061 
Research and development2,862 1,859 5,414 2,829 
Sales and marketing3,982 1,866 7,056 2,894 
General and administrative2,117 2,154 3,875 5,015 
Total stock-based compensation expense$11,353 $6,672 $20,859 $11,799